Biological Autoimmune Therapeutics
|発行||Greystone Research Associates||商品コード||745210|
Greystone Research Associates is pleased to announce the publication of a new market assessment. Biological Autoimmune Therapeutics: Drugs, Devices, Packaging, Therapeutics, Strategies and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for biological drugs for treating autoimmune conditions. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward user acceptance and designed-in usability. The influence of biosimilars on as-supplied packaging strategies is yet to be determined, but the need for product differentiation in an increasingly crowded market segment will make product packaging a key competitive factor.